Compare SFHG & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | CURX |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Hong Kong | United States |
| Employees | 226 | 6 |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 9.4M |
| IPO Year | N/A | 2025 |
| Metric | SFHG | CURX |
|---|---|---|
| Price | $2.46 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 69.7K |
| Earning Date | 10-30-2025 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.26 |
| 52 Week High | $3.17 | $9.18 |
| Indicator | SFHG | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 45.47 |
| Support Level | $2.29 | $0.32 |
| Resistance Level | $2.60 | $0.40 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 53.85 | 40.94 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.